Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75


TIM-3-Expressing Mast Cells Are Present in Chronic Rhinosinusitis with Nasal Polyps.

Corredera E, Phong BL, Moore JA, Kane LP, Lee SE.

Otolaryngol Head Neck Surg. 2018 May 1:194599818774560. doi: 10.1177/0194599818774560. [Epub ahead of print]


Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients.

Liu Z, McMichael EL, Shayan G, Li J, Chen K, Srivastava RM, Kane LP, Lu B, Ferris RL.

Clin Cancer Res. 2018 Apr 30. pii: clincanres.1350.2017. doi: 10.1158/1078-0432.CCR-17-1350. [Epub ahead of print]


Immune regulation by Tim-3.

Banerjee H, Kane LP.

F1000Res. 2018 Mar 14;7:316. doi: 10.12688/f1000research.13446.1. eCollection 2018. Review.


Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion.

Avery L, Filderman J, Szymczak-Workman AL, Kane LP.

Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2455-2460. doi: 10.1073/pnas.1712107115. Epub 2018 Feb 20.


Oral epithelial cells orchestrate innate type 17 responses to Candida albicans through the virulence factor candidalysin.

Verma AH, Richardson JP, Zhou C, Coleman BM, Moyes DL, Ho J, Huppler AR, Ramani K, McGeachy MJ, Mufazalov IA, Waisman A, Kane LP, Biswas PS, Hube B, Naglik JR, Gaffen SL.

Sci Immunol. 2017 Nov 3;2(17). pii: eaam8834. doi: 10.1126/sciimmunol.aam8834.


Treatment of mandibular osteomyelitis in two red-necked wallabies (Macropus rufogriseus) by means of intensive long-term parenteral drug administration and serial computed tomographic monitoring.

Kane LP, Langan JN, Adkesson MJ, Chinnadurai SK, Nevitt BN, Drees R.

J Am Vet Med Assoc. 2017 Nov 1;251(9):1070-1077. doi: 10.2460/javma.251.9.1070.


What Is Your Neurologic Diagnosis? Squamous cell carcinomas.

Kane LP, Hague DW, Lundberg A, Joslyn S.

J Am Vet Med Assoc. 2017 Aug 1;251(3):277-280. doi: 10.2460/javma.251.3.277. No abstract available.


Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients.

Jie HB, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL.

Cancer Immunol Res. 2017 May;5(5):408-416. doi: 10.1158/2326-6066.CIR-16-0333. Epub 2017 Apr 13.


Pharmacokinetics of nebulized and subcutaneously implanted terbinafine in cottonmouths (Agkistrodon piscivorus).

Kane LP, Allender MC, Archer G, Leister K, Rzadkowska M, Boers K, Souza M, Cox S.

J Vet Pharmacol Ther. 2017 Oct;40(5):575-579. doi: 10.1111/jvp.12406. Epub 2017 Apr 6.


TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.

Du W, Yang M, Turner A, Xu C, Ferris RL, Huang J, Kane LP, Lu B.

Int J Mol Sci. 2017 Mar 16;18(3). pii: E645. doi: 10.3390/ijms18030645. Review.


Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.

Shayan G, Srivastava R, Li J, Schmitt N, Kane LP, Ferris RL.

Oncoimmunology. 2016 Dec 23;6(1):e1261779. doi: 10.1080/2162402X.2016.1261779. eCollection 2017.


Inducible turnover of optineurin regulates T cell activation.

Montecalvo A, Watkins SC, Orange J, Kane LP.

Mol Immunol. 2017 May;85:9-17. doi: 10.1016/j.molimm.2017.01.027. Epub 2017 Feb 11.



Kane LP, Allender MC, Archer G, Dzhaman E, Pauley J, Moore AR, Ruiz MO, Smith RL, Byrd J, Phillips CA.

J Wildl Dis. 2017 Apr;53(2):285-295. doi: 10.7589/2016-06-138. Epub 2017 Jan 18.


Cutting Edge: Murine Mast Cells Rapidly Modulate Metabolic Pathways Essential for Distinct Effector Functions.

Phong B, Avery L, Menk AV, Delgoffe GM, Kane LP.

J Immunol. 2017 Jan 15;198(2):640-644. doi: 10.4049/jimmunol.1601150. Epub 2016 Dec 14.


Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk.

Li J, Shayan G, Avery L, Jie HB, Gildener-Leapman N, Schmitt N, Lu BF, Kane LP, Ferris RL.

Oncoimmunology. 2016 Sep 22;5(10):e1200778. eCollection 2016.


Dose-Dependent Suppression of Cytokine production from T cells by a Novel Phosphoinositide 3-Kinase Delta Inhibitor.

Way EE, Trevejo-Nunez G, Kane LP, Steiner BH, Puri KD, Kolls JK, Chen K.

Sci Rep. 2016 Jul 27;6:30384. doi: 10.1038/srep30384.


Development and validation of quantitative PCR for detection of Terrapene herpesvirus 1 utilizing free-ranging eastern box turtles (Terrapene carolina carolina).

Kane LP, Bunick D, Abd-Eldaim M, Dzhaman E, Allender MC.

J Virol Methods. 2016 Jun;232:57-61. doi: 10.1016/j.jviromet.2016.02.002. Epub 2016 Feb 10.


Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation.

Phong BL, Avery L, Sumpter TL, Gorman JV, Watkins SC, Colgan JD, Kane LP.

J Exp Med. 2015 Dec 14;212(13):2289-304. doi: 10.1084/jem.20150388. Epub 2015 Nov 23.


Cutting Edge: Differential Regulation of PTEN by TCR, Akt, and FoxO1 Controls CD4+ T Cell Fate Decisions.

Hawse WF, Sheehan RP, Miskov-Zivanov N, Menk AV, Kane LP, Faeder JR, Morel PA.

J Immunol. 2015 May 15;194(10):4615-9. doi: 10.4049/jimmunol.1402554. Epub 2015 Apr 8.


PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.

Li J, Jie HB, Lei Y, Gildener-Leapman N, Trivedi S, Green T, Kane LP, Ferris RL.

Cancer Res. 2015 Feb 1;75(3):508-518. doi: 10.1158/0008-5472.CAN-14-1215. Epub 2014 Dec 5.


Antigen receptor kinase two-step.

Kane LP.

J Immunol. 2014 Nov 1;193(9):4277-8. doi: 10.4049/jimmunol.1402287. No abstract available.


Complement component C5a permits the coexistence of pathogenic Th17 cells and type I IFN in lupus.

Pawaria S, Ramani K, Maers K, Liu Y, Kane LP, Levesque MC, Biswas PS.

J Immunol. 2014 Oct 1;193(7):3288-95. doi: 10.4049/jimmunol.1401322. Epub 2014 Aug 22.


Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion.

Ferris RL, Lu B, Kane LP.

J Immunol. 2014 Aug 15;193(4):1525-30. doi: 10.4049/jimmunol.1400557. Review.


T cell receptor-dependent activation of mTOR signaling in T cells is mediated by Carma1 and MALT1, but not Bcl10.

Hamilton KS, Phong B, Corey C, Cheng J, Gorentla B, Zhong X, Shiva S, Kane LP.

Sci Signal. 2014 Jun 10;7(329):ra55. doi: 10.1126/scisignal.2005169.


Phosphorylation of Carma1, but not Bcl10, by Akt regulates TCR/CD28-mediated NF-κB induction and cytokine production.

Cheng J, Hamilton KS, Kane LP.

Mol Immunol. 2014 May;59(1):110-6. doi: 10.1016/j.molimm.2014.01.011. Epub 2014 Feb 16.


The duration of T cell stimulation is a critical determinant of cell fate and plasticity.

Miskov-Zivanov N, Turner MS, Kane LP, Morel PA, Faeder JR.

Sci Signal. 2013 Nov 5;6(300):ra97. doi: 10.1126/scisignal.2004217.


TIM3 expression by leukemic and non-leukemic myeloblasts.

Roth CG, Garner K, Eyck ST, Boyiadzis M, Kane LP, Craig FE.

Cytometry B Clin Cytom. 2013 May;84(3):167-72. doi: 10.1002/cyto.b.21080. Epub 2013 Mar 29.


Global identification of genes and pathways regulated by Akt during activation of T helper cells.

Cheng J, Kane LP.

Version 2. F1000Res. 2013 Apr 15 [revised 2013 Jan 1];2:109. doi: 10.12688/f1000research.2-109.v2. eCollection 2013.


Inhibition of T-cell activation by PIK3IP1.

DeFrances MC, Debelius DR, Cheng J, Kane LP.

Eur J Immunol. 2012 Oct;42(10):2754-9. doi: 10.1002/eji.201141653. Epub 2012 Jul 19.


Murine Tim-1 is excluded from the immunological synapse.

Lin J, Chen L, Kane LP.

Version 2. F1000Res. 2012 Aug 10 [revised 2012 Jan 1];1:10. doi: 10.12688/f1000research.1-10.v2. eCollection 2012.


TIM polymorphisms--genetics and function.

Lee J, Phong B, Egloff AM, Kane LP.

Genes Immun. 2011 Dec;12(8):595-604. doi: 10.1038/gene.2011.75. Epub 2011 Nov 3. Review.


Akt fine-tunes NF-κB-dependent gene expression during T cell activation.

Cheng J, Phong B, Wilson DC, Hirsch R, Kane LP.

J Biol Chem. 2011 Oct 14;286(41):36076-85. doi: 10.1074/jbc.M111.259549. Epub 2011 Aug 23.


Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways.

Lee J, Su EW, Zhu C, Hainline S, Phuah J, Moroco JA, Smithgall TE, Kuchroo VK, Kane LP.

Mol Cell Biol. 2011 Oct;31(19):3963-74. doi: 10.1128/MCB.05297-11. Epub 2011 Aug 1.


Regulation of NF-κB induction by TCR/CD28.

Cheng J, Montecalvo A, Kane LP.

Immunol Res. 2011 Aug;50(2-3):113-7. doi: 10.1007/s12026-011-8216-z. Review.


Are TIM proteins involved in asthma development or pathology?

Lin J, Kane LP.

Clin Exp Allergy. 2011 Jul;41(7):917-9. doi: 10.1111/j.1365-2222.2011.03771.x. Epub 2011 May 30. No abstract available.


Galectin-9 regulates T helper cell function independently of Tim-3.

Su EW, Bi S, Kane LP.

Glycobiology. 2011 Oct;21(10):1258-65. doi: 10.1093/glycob/cwq214. Epub 2010 Dec 27.


IL-17RC is required for immune signaling via an extended SEF/IL-17R signaling domain in the cytoplasmic tail.

Ho AW, Shen F, Conti HR, Patel N, Childs EE, Peterson AC, Hernández-Santos N, Kolls JK, Kane LP, Ouyang W, Gaffen SL.

J Immunol. 2010 Jul 15;185(2):1063-70. doi: 10.4049/jimmunol.0903739. Epub 2010 Jun 16.


T cell Ig and mucin domain proteins and immunity.

Kane LP.

J Immunol. 2010 Mar 15;184(6):2743-9. doi: 10.4049/jimmunol.0902937. Review.


Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling.

Hu W, Nessler S, Hemmer B, Eagar TN, Kane LP, Leliveld SR, Müller-Schiffmann A, Gocke AR, Lovett-Racke A, Ben LH, Hussain RZ, Breil A, Elliott JL, Puttaparthi K, Cravens PD, Singh MP, Petsch B, Stitz L, Racke MK, Korth C, Stüve O.

Brain. 2010 Feb;133(Pt 2):375-88. doi: 10.1093/brain/awp298. Epub 2010 Feb 9.


Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion.

Turner MS, Kane LP, Morel PA.

J Immunol. 2009 Oct 15;183(8):4895-903. doi: 10.4049/jimmunol.0901459.


Aberrant TGF-beta signaling reduces T regulatory cells in ICAM-1-deficient mice, increasing the inflammatory response to Mycobacterium tuberculosis.

Windish HP, Lin PL, Mattila JT, Green AM, Onuoha EO, Kane LP, Flynn JL.

J Leukoc Biol. 2009 Sep;86(3):713-25. doi: 10.1189/jlb.1208740. Epub 2009 May 19. Erratum in: J Leukoc Biol. 2014 Sep;96(3):503-504. J Leukoc Biol. 2014 Sep;96(3):503-4.


TIM-1 and TIM-3 proteins in immune regulation.

Su EW, Lin JY, Kane LP.

Cytokine. 2008 Oct;44(1):9-13. doi: 10.1016/j.cyto.2008.06.013. Epub 2008 Aug 15. Review.


Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo.

Sasaki K, Zhao X, Pardee AD, Ueda R, Fujita M, Sehra S, Kaplan MH, Kane LP, Okada H, Storkus WJ.

J Immunol. 2008 Jul 1;181(1):104-8.


T cell Ig and mucin domain-1-mediated T cell activation requires recruitment and activation of phosphoinositide 3-kinase.

de Souza AJ, Oak JS, Jordanhazy R, DeKruyff RH, Fruman DA, Kane LP.

J Immunol. 2008 May 15;180(10):6518-26.


Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells.

Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW, Hirashima M, Bruce JN, Kane LP, Kuchroo VK, Hafler DA.

Science. 2007 Nov 16;318(5853):1141-3.


TIM family proteins and autoimmunity.

Kane LP.

Autoimmunity. 2007 Sep;40(6):405-8. Review.


Immune regulation by the TIM gene family.

de Souza AJ, Kane LP.

Immunol Res. 2006;36(1-3):147-55. Review.


Cutting edge: inhibition of T cell activation by TIM-2.

Knickelbein JE, de Souza AJ, Tosti R, Narayan P, Kane LP.

J Immunol. 2006 Oct 15;177(8):4966-70.


CARMA1 is required for Akt-mediated NF-kappaB activation in T cells.

Narayan P, Holt B, Tosti R, Kane LP.

Mol Cell Biol. 2006 Mar;26(6):2327-36.


T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation.

de Souza AJ, Oriss TB, O'malley KJ, Ray A, Kane LP.

Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17113-8. Epub 2005 Nov 11.

Supplemental Content

Support Center